Triple Combination Ophthalmic Solution for Glaucoma IOP Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly in patients with chronic open-angle glaucoma or ocular hypertension, often fail to adequately lower intraocular pressure (IOP) with mono or dual combination therapies, necessitating the need for more effective IOP-lowering agents.
Innovation Solution
A Triple Combination therapy comprising bimatoprost, brimonidine, and timolol, along with additional ingredients like sodium phosphate dibasic heptahydrate, citric acid monohydrate, sodium chloride, and benzalkonium chloride, is administered topically to enhance IOP reduction while maintaining safety and tolerability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If mono or dual combination therapies are used for lowering intraocular pressure, then treatment simplicity is maintained, but IOP lowering efficacy is insufficient
Solution Approach 1:
The patent combines three distinct IOP-lowering agents (bimatoprost, brimonidine, and timolol) into a single fixed combination ophthalmic solution. This merging approach allows the treatment to maintain simplicity of administration (single drop) while achieving superior IOP lowering efficacy through the synergistic effects of all three active ingredients working together.
2Reliability
If Triple Combination therapy is used to maximize IOP reduction, then IOP lowering efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent formulates three separate ophthalmic medications into one fixed combination solution, eliminating the need for patients to administer multiple separate drops. This single-drop Triple Combination therapy achieves maximum IOP lowering efficacy while simplifying the treatment regimen and reducing administrative burden on both patients and healthcare providers.
3Reliability
If multiple IOP-lowering agents are combined, then IOP reduction effectiveness is enhanced, but risk of adverse effects increases
Solution Approach 1:
The patent utilizes the complementary mechanisms of action of three different drug classes (prostamide, alpha-2 adrenergic agonist, and beta-blocker) to achieve enhanced IOP reduction through multiple pathways. By targeting different physiological mechanisms, the fixed combination can achieve superior efficacy while potentially reducing the risk of adverse effects associated with high doses of any single agent.
Data Source
AI summary
Disclosed herein are compositions for lowering intraocular pressure (IOP) of an eye comprising a combination IOP-lowering agents bimatoprost, brimonidine, and timolol. Further disclosed are methods for reducing IOP in the eye of a subject.